Wave Life Sciences Ltd. (NASDAQ:WVE) is one of the top 12 genomics stocks to invest in. H.C. Wainwright upgraded WVE’s price target to $30, citing significant fat loss and lean mass gain with no side effects for WVE-007. Visible Alpha reported a 147% surge in WVE shares after positive clinical data for the obesity therapy.

Visible Alpha predicts that WVE-007 could generate $68 million in revenue by 2030 and $2.1 billion by 2040, contributing up to 47% of the company’s revenue. Wave Life Sciences focuses on RNA therapies to improve human health. While WVE shows promise, other AI stocks may offer greater potential and lower risks.

For more investment options, consider exploring high-growth EV stocks and top car stocks for 2025. No disclosures were made in the report.

Read more at Yahoo Finance: H.C. Wainwright Maintains A Buy Rating On Wave Life Sciences Ltd. (WVE)